Beaver Andrei F. Dayo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beaver Andrei F. Dayo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Allan Patrick Gose Macabeo
Institut fur Organische Chemie, Universität Regensburg, Universitätsstr. 31, 93053 Regensburg, Germany; School of Criminal Justice Education, Ilocos Sur Polytechnic State College – Main Campus, Candon City, 2710 Ilocos Sur, Philippines
1 shared publication - Joe Anthony H. Manzano
College of Science University of Santo Tomas Manila Philippines
1 shared publication - John Cyril D. Abanto
Department of Chemistry, College of Science, University of Santo Tomas, Manila, Philippines
1 shared publication - Lloyd Christian Jamilano-Llames
Research Center for the Natural and Applied Sciences, University of Santo Tomas, Manila, Philippines
1 shared publication Mary Grace E. Gonzaga
College of Arts and Sciences, President Ramon Magsaysay State University, Iba, Philippines
1 shared publication- Simone Brogi
Department of Pharmacy University of Pisa Pisa Italy
1 shared publication
Latest Publications
- 28 August 2025
- Published by Springer Nature in Archives of Microbiology
- Vol. 207 (10) , 1-19
DNA gyrase-inhibitory antimicrobial anthraquinone from the endophytic Sordariomycetes fungus Diaporthe perseae
Fungi of the order Diaporthales are prolific sources of antimicrobial secondary metabolites. In this paper, we describe antimicrobial and antituberculosis anthraquinones (AQs) from Diaporthe perseae, an endophytic fungus isolated and identified from the endemic Philippine medicinal plant Uvaria alba (Annonaceae). Large-scale rice fermentation of D. perseae yielded an ethyl acetate extract which was subjected to a series of chromatographic purification to yield three compounds. Spectroscopic analyses allowed the identification of the anthraquinone compounds citreorosein (1), skyrin (2), and rugulosin A (3). AQs 1 and 3 showed broad-spectrum against Gram-positive bacteria (Micrococcus luteus, Bacillus subtilis, and Staphylococcus aureus) (MIC = 1.0–2.0 µg/mL), however only 3 demonstrated strong inhibition against Gram-negative bacterial strains (Escherichia coli, Pseudomonas aeruginosa, and Chromobacterium violaceum) and non-TB mycobacteria (Mycobacterium smegmatis) (MIC = 8.25–66.0 µg/mL). AQ 3 also exhibited inhibition against both M. tuberculosis (Mtb) H37Rv (Microplate Alamar Blue Assay; MABA MIC = 29.2 µg/mL) and its non-replicating persistent strain (Low-Oxygen Recovery Assay; LORA MIC = 30.3 µg/mL). To explore the potential mechanism of 3, DNA supercoiling assay was performed. Thus, rugulosin A (3) displayed inhibition of Mtb. DNA gyrase, an enzyme necessary for genomic replication via ATP-dependent DNA relaxation mechanisms. Molecular docking and molecular dynamics revealed strong, stable binding affinity of 3 (BE = -9.5 kcal/mol) and its tautomer 4 (BE = -9.6 kcal/mol) within the active pocket of the MtbDNA gyrase. Overall, rugulosin A (3) represents a promising antibiotic prototype with in vitro and in silico activity against M. tuberculosis, and identifies DNA gyrase as therapeutic target for anthraquinone antimycobacterials.
- 28 August 2025
- Published by Springer Nature in Archives of Microbiology
- Vol. 207 (10) , 1-19
DNA gyrase-inhibitory antimicrobial anthraquinone from the endophytic Sordariomycetes fungus Diaporthe perseae
Fungi of the order Diaporthales are prolific sources of antimicrobial secondary metabolites. In this paper, we describe antimicrobial and antituberculosis anthraquinones (AQs) from Diaporthe perseae, an endophytic fungus isolated and identified from the endemic Philippine medicinal plant Uvaria alba (Annonaceae). Large-scale rice fermentation of D. perseae yielded an ethyl acetate extract which was subjected to a series of chromatographic purification to yield three compounds. Spectroscopic analyses allowed the identification of the anthraquinone compounds citreorosein (1), skyrin (2), and rugulosin A (3). AQs 1 and 3 showed broad-spectrum against Gram-positive bacteria (Micrococcus luteus, Bacillus subtilis, and Staphylococcus aureus) (MIC = 1.0–2.0 µg/mL), however only 3 demonstrated strong inhibition against Gram-negative bacterial strains (Escherichia coli, Pseudomonas aeruginosa, and Chromobacterium violaceum) and non-TB mycobacteria (Mycobacterium smegmatis) (MIC = 8.25–66.0 µg/mL). AQ 3 also exhibited inhibition against both M. tuberculosis (Mtb) H37Rv (Microplate Alamar Blue Assay; MABA MIC = 29.2 µg/mL) and its non-replicating persistent strain (Low-Oxygen Recovery Assay; LORA MIC = 30.3 µg/mL). To explore the potential mechanism of 3, DNA supercoiling assay was performed. Thus, rugulosin A (3) displayed inhibition of Mtb. DNA gyrase, an enzyme necessary for genomic replication via ATP-dependent DNA relaxation mechanisms. Molecular docking and molecular dynamics revealed strong, stable binding affinity of 3 (BE = -9.5 kcal/mol) and its tautomer 4 (BE = -9.6 kcal/mol) within the active pocket of the MtbDNA gyrase. Overall, rugulosin A (3) represents a promising antibiotic prototype with in vitro and in silico activity against M. tuberculosis, and identifies DNA gyrase as therapeutic target for anthraquinone antimycobacterials.